Next Article in Journal
Comparison of Perioperative Chemotherapy versus Postoperative Chemoradiotherapy for Operable Stomach Cancer: A Western Canadian Province Experience
Previous Article in Journal
Multicenter Study of the Seroprevalence of Antibodies against Covid-19 in Patients with Lymphoma: An Analysis of the Oncological Group for the Treatment and Study of Lymphomas (Gotel)
Open AccessBrief Report

Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial

Canadian Cancer Trials Group, Queen’s University, Kingston, ON K7L 3N6, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2021, 28(2), 1256-1261; https://doi.org/10.3390/curroncol28020119
Received: 14 January 2021 / Revised: 10 February 2021 / Accepted: 11 March 2021 / Published: 17 March 2021
We conducted an analysis of indirect costs alongside the LY.12 randomized trial in patients with relapsed or refractory (R/R) aggressive non-Hodgkin lymphoma (NHL). Lost productivity data for Canadian patients and caregivers in the trial were collected at baseline and with each chemotherapy cycle pre-transplant, using an adapted Lost Productivity questionnaire. Mean per patient indirect costs were CAD 2999 for patients in the GDP arm and CAD 3400 in the DHAP arm. A substantial majority was not working or had to reduce their workload during this treatment time. Salvage chemotherapy for R/R aggressive NHL is associated with significant indirect costs to patients and their caregivers. View Full-Text
Keywords: lymphoma; autologous stem cell transplantation; cost-effectiveness analysis lymphoma; autologous stem cell transplantation; cost-effectiveness analysis
MDPI and ACS Style

Prica, A.; Hay, A.E.; Crump, M.; Mittmann, N.; Shepherd, L.E.; Meyer, R.M.; Imrie, K.I.; Risebrough, N.; Djurfeldt, M.; Chen, B.E.; Cheung, M.C. Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial. Curr. Oncol. 2021, 28, 1256-1261. https://doi.org/10.3390/curroncol28020119

AMA Style

Prica A, Hay AE, Crump M, Mittmann N, Shepherd LE, Meyer RM, Imrie KI, Risebrough N, Djurfeldt M, Chen BE, Cheung MC. Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial. Current Oncology. 2021; 28(2):1256-1261. https://doi.org/10.3390/curroncol28020119

Chicago/Turabian Style

Prica, Anca; Hay, Annette E.; Crump, Michael; Mittmann, Nicole; Shepherd, Lois E.; Meyer, Ralph M.; Imrie, Kevin I.; Risebrough, Nancy; Djurfeldt, Marina; Chen, Bingshu E.; Cheung, Matthew C. 2021. "Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial" Curr. Oncol. 28, no. 2: 1256-1261. https://doi.org/10.3390/curroncol28020119

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop